The Types segment categorizes DNA Methylation Chips by underlying technology and design architecture, influencing cost structures and adoption rates. Array‑based chips dominate with fixed probe sets that enable standardized, reproducible assays across laboratories; they represent the bulk of commercial offerings due to economies of scale. BeadChip platforms, a subset of array technology, provide flexible multiplexing and are favored in large epidemiological studies for their high sample throughput. Infinium technology, another array variant, combines single‑base resolution with robust data quality, attracting academic and clinical research groups. Custom‑designed chips occupy a niche, allowing bespoke probe selection for rare disease panels or proprietary biomarker panels, albeit at higher per‑sample cost. Finally, emerging next‑generation sequencing‑linked chips integrate hybrid capture with sequencing, offering deeper methylome coverage. Each type contributes to market dynamics by aligning performance characteristics with the analytical requirements of the application sub‑segments, reinforcing the market taxonomy.